The impact of acute rejection on the development of intimal hyperplasia associated with chronic rejection.

The rat aortic model of chronic rejection was used to study the effect of acute rejection on the development of intimal hyperplasia (IH). Two model systems were studied. In the first, continuous monotherapy with mycophenolate mofetil (MM) (40 mg/dx14 d followed by 30 mg/kg/d) was initiated 2 or 4 weeks posttransplant. Digital computer image analysis was used to quantify IH. While the development of IH was delayed, it was not prevented. In allografts where MM treatment was delayed for 2 wk, a 35.5% reduction in the amount of IH was observed. Delaying drug treatment for 4 wk resulted in a 42.2% reduction of IH. In contrast, continuous therapy from the time of transplant resulted in a 76.3% reduction in the amount of IH in comparison with untreated allograft controls. To further define the role of acute rejection in the development of IH, aortic allografts, ACI or (ACIxLewis)F1 (F1), were orthotopically transplanted to Lewis recipients and then retransplanted to donor strain secondary recipients after 2 or 4 wk. Grafts were harvested at 12 weeks posttransplant. When the retransplant was performed at 2 wk, intimal hyperplasia was decreased by 55.9% in ACI and by 66.7% in F1 allografts in comparison to conventional (ACI-->Lewis) allograft controls. When retransplantation was delayed until 4 wk, IH was not decreased in ACI allografts (105.9%) and was only marginally decreased in F1 allografts (26.2%). Syngeneic control F1 grafts (F1-->F1-->F1) did not develop significant IH at 12 or 20 wk when retransplanted at 2 wk (10% and 12%, respectively) or when retransplanted at 4 wk and harvested at 12 wk (18.6%). A common feature of IH is the development of medial acellularity. Unlike conventional allograft recipients (ACI-->Lewis; no retransplantation), F1 retransplanted grafts did not develop significant medial myocyte dropout. In contrast, delayed MM immunosuppressive therapy or retransplantation of ACI allografts at 4 weeks to ACI secondary recipients resulted in significant loss of medial myocytes. Our results show that acute rejection, which occurs during the first 4 wk posttransplant, is sufficient to mediate the development of IH associated with CR. However the lack of a continued allogenic environment slows the process.

[1]  M. Myllärniemi,et al.  Lack of effect of recombinant human superoxide dismutase on cold ischemia-induced arteriosclerosis in syngeneic rat aortic transplants. , 1996, Transplantation.

[2]  D. Stablein,et al.  Clinical correlates of chronic rejection in pediatric renal transplantation. A report of the North American Pediatric Renal Transplant Cooperative Study. , 1996, Transplantation.

[3]  J. Geraghty,et al.  INHIBITION OF INTIMAL HYPERPLASIA IN RAT AORTIC ALLOGRAFTS WITH CYCLOSPORINE , 1995, Transplantation.

[4]  K. Lemström,et al.  Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. , 1994, Circulation.

[5]  U. Heemann,et al.  REVERSIBILITY OF CHRONIC RENAL ALLOGRAFT REJECTION: Critical Effect of Time After Transplantation Suggests Both Host Immune Dependent and Independent Phases of Progressive Injury1 , 1994, Transplantation.

[6]  D. Dunn,et al.  Early versus late acute renal allograft rejection: impact on chronic rejection. , 1993 .

[7]  D. Dunn,et al.  Risk factors for chronic rejection in renal allograft recipients. , 1993, Transplantation.

[8]  P. Belitsky,et al.  THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTS , 1992, Transplantation.

[9]  T. Strom,et al.  Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal allografts. , 1991, Annals of Surgery.

[10]  Cecka Jm Early rejection: determining the fate of renal transplants. , 1991 .

[11]  T. Paavonen,et al.  Rat aortic allografts: an experimental model for chronic transplant arteriosclerosis. , 1991, Transplantation proceedings.

[12]  T. Paavonen,et al.  Chronic rejection of rat aortic allograft: II. Administration of cyclosporin induces accelerated allograft arteriosclerosis , 1991, Transplant international : official journal of the European Society for Organ Transplantation.

[13]  D. Eckhoff,et al.  RS-61443--a new, potent immunosuppressive agent. , 1991, Transplantation.

[14]  R. Blamey,et al.  Characteristics of cadaveric renal allograft recipients developing chronic rejection. , 1990, Annals of the Royal College of Surgeons of England.

[15]  H. Sollinger,et al.  Enhancement of thyroid allograft survival following organ culture. Alteration of tissue immunogenicity. , 1989, Transplantation.

[16]  E. Blackstone,et al.  Important Risk Factors of Allograft Survival in Cadaveric Renal Transplantation A Study of 426 Patients , 1988, Annals of surgery.

[17]  B. Hall,et al.  Cells mediating allograft rejection. , 1991, Immunological reviews.